Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 23, 2018 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company will hold its Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis®(dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]
Investor Relations
United States:
The Trout Group
Marcy Nanus
+1 646-378-2927
[email protected]
Europe:
First House
Mitra Hagen Negård
+47 21 04 62 19
[email protected]
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
